Bicycle Therapeutics plc
BCYC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.11 | -0.11 | -0.18 | -60.73 |
| FCF Yield | -20.37% | -9.88% | -11.97% | -1.10% |
| EV / EBITDA | 0.33 | -0.88 | -5.44 | -17.65 |
| Quality | ||||
| ROIC | -22.80% | -35.79% | -31.94% | -14.36% |
| Gross Margin | -390.34% | -480.13% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.97 | 0.34 | 0.76 | 0.22 |
| Growth | ||||
| Revenue 3-Year CAGR | 34.61% | 32.12% | 11.66% | 2,269,894.63% |
| Free Cash Flow Growth | -161.12% | 39.53% | -524.69% | 11.40% |
| Safety | ||||
| Net Debt / EBITDA | 5.28 | 2.63 | 2.75 | 6.15 |
| Interest Coverage | -121.31 | -58.21 | -34.88 | -21.99 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 335.58 | 294.82 | 535.20 | 371.65 |